[go: up one dir, main page]

WO2004069167A3 - Methode et compositions pour le traitement de l'infertilite masculine - Google Patents

Methode et compositions pour le traitement de l'infertilite masculine Download PDF

Info

Publication number
WO2004069167A3
WO2004069167A3 PCT/US2004/002400 US2004002400W WO2004069167A3 WO 2004069167 A3 WO2004069167 A3 WO 2004069167A3 US 2004002400 W US2004002400 W US 2004002400W WO 2004069167 A3 WO2004069167 A3 WO 2004069167A3
Authority
WO
WIPO (PCT)
Prior art keywords
ejaculatory
ovum
apomorphine
fertilization
examples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/002400
Other languages
English (en)
Other versions
WO2004069167A2 (fr
Inventor
Steven C Quay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marina Biotech Inc
Original Assignee
MDRNA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MDRNA Inc filed Critical MDRNA Inc
Publication of WO2004069167A2 publication Critical patent/WO2004069167A2/fr
Publication of WO2004069167A3 publication Critical patent/WO2004069167A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'utilisation d'agents permettant d'améliorer l'éjaculation permet de traiter des hommes présentant des spermatogrammes présentant un faible décompte de spermatozoïdes pour favoriser la fertilisation d'un ovule. Des agents d'amélioration de l'éjaculation sont utilisés pour favoriser des éjaculations plus fréquentes, ce qui permet de produire plus de sperme, et ainsi d'accroître la probabilité de fertilisation de l'ovule, puisque plus de sperme est disponible. La fertilisation de l'ovule peut s'effectuer par un rapport sexuel avec une femme, ou par fertilisation in vitro ou par insémination artificielle. Des exemples d'agents d'amélioration de l'éjaculation sont des agonistes du récepteur de la dopamine, des inhibiteurs spécifiques de la phosphodiestérase-5 (PDE-V), des nitrates organiques, de l'arginine L et des combinaisons de ceux-ci. Les agonistes du récepteur de la dopamine comprennent de l'apomorphine, un sel d'ajout pharmaceutiquement acceptable de l'apomorphine, et un dérivé de l'apomorphine, de la bromocriptine, du ropinirole, de la cabergoline, du pramipexole, du roxindole et du lisuride. Des exemples d'inhibiteurs de PDE-V comprennent le sildenafil, le tadalafil et le vardenafil. Des exemples de nitrates organiques comprennent du trinitrate de glycérol, du nitrure d'amyle, du dinitrate d'isosorbide, de l'isosorbide-5-mononitrate et du tétranitrate d'érythrityle.
PCT/US2004/002400 2003-01-31 2004-01-27 Methode et compositions pour le traitement de l'infertilite masculine Ceased WO2004069167A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44403203P 2003-01-31 2003-01-31
US60/444,032 2003-01-31

Publications (2)

Publication Number Publication Date
WO2004069167A2 WO2004069167A2 (fr) 2004-08-19
WO2004069167A3 true WO2004069167A3 (fr) 2004-10-28

Family

ID=32850819

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/002400 Ceased WO2004069167A2 (fr) 2003-01-31 2004-01-27 Methode et compositions pour le traitement de l'infertilite masculine

Country Status (1)

Country Link
WO (1) WO2004069167A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
KR20080047375A (ko) 2005-07-29 2008-05-28 콘서트 파마슈티컬즈, 인크. 약제 화합물
AU2008216356C1 (en) * 2007-02-12 2014-07-24 Aytu Bioscience, Inc. Treatment of comorbid premature ejaculation and erectile dysfunction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6338862B1 (en) * 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
US6506765B2 (en) * 2000-04-07 2003-01-14 Tap Pharmaceutical Products, Inc. Apomorphine derivatives and methods for their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506765B2 (en) * 2000-04-07 2003-01-14 Tap Pharmaceutical Products, Inc. Apomorphine derivatives and methods for their use
US6338862B1 (en) * 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors

Also Published As

Publication number Publication date
WO2004069167A2 (fr) 2004-08-19

Similar Documents

Publication Publication Date Title
JP4248239B2 (ja) プリン作用性レセプターアンタゴニストとしてのピロロ［２，３−ｄ］ピリミジンおよびそれらの使用
BR0109577A (pt) Composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, método para tratar cânceres em um animal de sangue quente
MY128479A (en) (beta)-carboline derivatives useful as inhibitors of phosphodiesterase
CA2677691A1 (fr) Reduction des effets secondaires du tramadol
WO2001041807A3 (fr) Administration a travers les muqueuses d'inhibiteurs de la phosphodiesterase dans le traitement de la dyserection
CA2360668A1 (fr) Utilisation de derives du 4-h-1-benzopyran-4-one comme inhibiteurs de la proliferation des cellules de muscles lisses
AU6797394A (en) Pyrazolopyrimidinones for the treatment of impotence
EP1505068A4 (fr) DERIVE DE PYRAZOLO(1,5-a)PYRIMIDINE ET INHIBITEUR DE LA NAD(P)H OXYDASE CONTENANT LEDIT DERIVE
GT200000168A (es) Compuestos farmaceuticamente activos.
RU2011133242A (ru) Фармацевтические композиции и их применение в лечении женской сексуальной дисфункции
MX337817B (es) Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas.
WO2005034845A8 (fr) Compositions et methodes de traitement du cancer
EA200200337A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[4,3-d]ПИРИМИДИНА
RU2009120990A (ru) Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции
MA31594B1 (fr) Composes organiques
WO2008070313A3 (fr) Dérivés de 3-(dihydro-1h-pyrazolo [4,3-d]pyrimidin-5-yl)-4-propoxybenzènesulfonamide et procédés d'utilisation
Maw et al. Design, synthesis and biological activity of β-carboline-based type-5 phosphodiesterase inhibitors
PE20040978A1 (es) Compuestos antiinflamatorios de di y trifluoro-triazolo-piridinas
CO5170493A1 (es) Articulos de fabricacion
WO2006104762A3 (fr) Traitement d'humains de sexe masculin par supplementation en testosterone associee a un inhibiteur de 5alpha-reductase
WO2004069167A3 (fr) Methode et compositions pour le traitement de l'infertilite masculine
CL2021003530A1 (es) Hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina solicitud divisional de solicitud 2284-2020.
MY133527A (en) Isoquinoline derivatives
CA2677690A1 (fr) Traitement destine a une ejaculation precoce et aux troubles de l'erection comorbides
SI1572214T1 (sl) Derivati morfolina za uporabo kot dopaminski agonisti pri zdravljenju med drugim spolne disfunkcije

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase